Pulse Biosciences Up 16% on Product Updates, Potential Stock Purchases by Duggan
By Josh Beckerman
Pulse Biosciences shares rose 16% after the bioelectric medicine company issued product updates and said controlling stockholder and Chairman Robert W. Duggan is evaluating potential purchases of company stock.
The stock was recently at $8.47 and has more than quadrupled over the last 52 weeks.
Pulse has received all regulatory approvals for a planned catheter ablation feasibility study for its CellFX nsPFA Cardiac Catheter and said the first study procedures are scheduled for mid-December.
Additionally, Pulse said it anticipates filing a 510(k) submission with the Food and Drug Administration for its CellFX nsPFA Cardiac Clamp by the end of the January, and said a December filing is possible.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
November 27, 2023 15:36 ET (20:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
United States